{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:33:34Z","timestamp":1790210014656,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11940-012-0175-8","type":"journal-article","created":{"date-parts":[[2012,4,30]],"date-time":"2012-04-30T05:52:39Z","timestamp":1335765159000},"page":"230-240","source":"Crossref","is-referenced-by-count":22,"title":["Considerations Regarding the Etiology and Future Treatment of Autosomal Recessive Versus Idiopathic Parkinson Disease"],"prefix":"10.1007","volume":"14","author":[{"given":"Tohru","family":"Kitada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianna J.","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hei Sio","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Schlossmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,1]]},"reference":[{"issue":"3","key":"175_CR1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11940-006-0013-y","volume":"8","author":"D Tarsy","year":"2006","unstructured":"Tarsy D. Initial treatment of Parkinson\u2019s disease. Curr Treat Options Neurol. 2006;8(3):224\u201335.","journal-title":"Curr Treat Options Neurol"},{"issue":"6","key":"175_CR2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11940-001-0012-y","volume":"3","author":"JM Bertoni","year":"2001","unstructured":"Bertoni JM, Prendes JL, Sprenkle P. Long-term Medical Treatment for Parkinson\u2019s Disease. Curr Treat Options Neurol. 2001;3(6):495\u2013506.","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"175_CR3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11940-010-0067-8","volume":"12","author":"VK Hinson","year":"2010","unstructured":"Hinson VK. Parkinson\u2019s disease and motor fluctuations. Curr Treat Options Neurol. 2010;12(3):186\u201399.","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"175_CR4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF02938410","volume":"9","author":"J Rao","year":"2007","unstructured":"Rao J. Treatment of Levodopa-induced Dyskinesia. Curr Treat Options Neurol. 2007;9(3):205\u20139.","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"175_CR5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11940-003-0004-1","volume":"5","author":"H Bronte-Stewart","year":"2003","unstructured":"Bronte-Stewart H. Parkinson\u2019s Disease: Surgical Options. Curr Treat Options Neurol. 2003;5(2):131\u201347.","journal-title":"Curr Treat Options Neurol"},{"key":"175_CR6","unstructured":"Wilkinson JR, Weintraub D, and Stern MB. Clinical Manifestations of Parkinson\u2019s Disease. In: Watts RL, Standaert DG, and Obeso JA, editors. Movement Disorders, 3rd Edition. McGraw-Hill; 2012. p. 229\u201346."},{"issue":"2","key":"175_CR7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/archneur.1993.00540020018011","volume":"50","author":"AJ Hughes","year":"1993","unstructured":"Hughes AJ et al. JNNP 1992;55:181\u2013184.","journal-title":"Arch Neurol"},{"issue":"4","key":"175_CR8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","volume":"20","author":"H Bernheimer","year":"1973","unstructured":"Bernheimer H, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20(4):415\u201355.","journal-title":"J Neurol Sci"},{"issue":"3","key":"175_CR9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1212\/WNL.23.3.239","volume":"23","author":"Y Yamamura","year":"1973","unstructured":"Yamamura Y, et al. Paralysis agitans of early onset with marked diurnal fluctuation of symptoms. Neurology. 1973;23(3):239\u201344.","journal-title":"Neurology"},{"issue":"5","key":"175_CR10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","volume":"110","author":"H Braak","year":"2003","unstructured":"Braak H, et al. Idiopathic Parkinson\u2019s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110(5):517\u201336.","journal-title":"J Neural Transm"},{"key":"175_CR11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1749-6632.2009.04365.x","volume":"1170","author":"CH Hawkes","year":"2009","unstructured":"Hawkes CH, Del Tredici K, Braak H. Parkinson\u2019s disease: the dual hit theory revisited. Ann N Y Acad Sci. 2009;1170:615\u201322.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"175_CR12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","volume":"44","author":"A Zimprich","year":"2004","unstructured":"Zimprich A, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601\u20137.","journal-title":"Neuron"},{"issue":"3","key":"175_CR13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.20587","volume":"58","author":"PP Pramstaller","year":"2005","unstructured":"Pramstaller PP, et al. Lewy body Parkinson\u2019s disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol. 2005;58(3):411\u201322.","journal-title":"Ann Neurol"},{"issue":"5","key":"175_CR14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/bmm.10.93","volume":"4","author":"MG Schlossmacher","year":"2010","unstructured":"Schlossmacher MG, Mollenhauer B. Biomarker research in Parkinson\u2019s disease: objective measures needed for patient stratification in future cause-directed trials. Biomark Med. 2010;4(5):647\u201350.","journal-title":"Biomark Med"},{"issue":"6","key":"175_CR15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/archneurol.2011.11","volume":"68","author":"C Klein","year":"2011","unstructured":"Klein C, et al. Translational research in neurology and neuroscience 2011: movement disorders. Arch Neurol. 2011;68(6):709\u201316.","journal-title":"Arch Neurol"},{"issue":"3","key":"175_CR16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncpneuro0126","volume":"2","author":"C Klein","year":"2006","unstructured":"Klein C, Schlossmacher MG. The genetics of Parkinson disease: Implications for neurological care. Nat Clin Pract Neurol. 2006;2(3):136\u201346.","journal-title":"Nat Clin Pract Neurol"},{"key":"175_CR17","unstructured":"Marras C, and Tanner CM. Epidemiology of Parkinson\u2019s disease. In: Watts RL, Standaert DG, and Obeso JA, editors. Movement Disorders, 3rd Edition, McGraw-Hill; 2012. p. 169\u201392."},{"key":"175_CR18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrg1831","volume":"7","author":"MJ Farrer","year":"2006","unstructured":"Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006;7:306\u201318.","journal-title":"Nat Rev Genet"},{"issue":"7","key":"175_CR19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S1474-4422(07)70174-6","volume":"6","author":"C Klein","year":"2007","unstructured":"Klein C, et al. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol. 2007;6(7):652\u201362.","journal-title":"Lancet Neurol"},{"issue":"5","key":"175_CR20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat Med. 2008;14(5):504\u20136.","journal-title":"Nat Med"},{"issue":"5","key":"175_CR21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"JY Li","year":"2008","unstructured":"Li JY, et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501\u20133.","journal-title":"Nat Med"},{"issue":"2","key":"175_CR22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","volume":"213","author":"B Mollenhauer","year":"2008","unstructured":"Mollenhauer B, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008;213(2):315\u201325.","journal-title":"Exp Neurol"},{"issue":"17","key":"175_CR23","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361(17):1651\u201361.","journal-title":"N Engl J Med"},{"key":"175_CR24","doi-asserted-by":"crossref","unstructured":"Sardi SP, et al. Mutant GBA1 expression and Synucleinopathy risk: First insights from cellular and mouse models. Neurodegener Dis, 2012.","DOI":"10.1159\/000335038"},{"issue":"7","key":"175_CR25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1056\/NEJM200502173520719","volume":"352","author":"MJ Eblan","year":"2005","unstructured":"Eblan MJ, Walker JM, Sidransky E. The glucocerebrosidase gene and Parkinson\u2019s disease in Ashkenazi Jews. N Engl J Med. 2005;352(7):728\u201331. author reply 728\u201331.","journal-title":"N Engl J Med"},{"key":"175_CR26","doi-asserted-by":"crossref","unstructured":"Tomlinson JJ, Cullen V, and Schlossmacher MG. Identifying targets in alpha-Synuclein metabolism to treat Parkinson\u2019s and related disorders, in protein misfolding diseases: Current and emerging principles and therapies, In: Ramirez-Alvaro M, Kelly JW, and Dobson CM, editors. Wiley & Sons 2010.","DOI":"10.1002\/9780470572702.ch37"},{"issue":"9","key":"175_CR27","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.2199","volume":"16","author":"BD Lee","year":"2010","unstructured":"Lee BD, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson\u2019s disease. Nat Med. 2010;16(9):998\u20131000.","journal-title":"Nat Med"},{"issue":"11","key":"175_CR28","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/ni.2113","volume":"12","author":"Z Liu","year":"2011","unstructured":"Liu Z, et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol. 2011;12(11):1063\u201370.","journal-title":"Nat Immunol"},{"issue":"5","key":"175_CR29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00702-011-0653-2","volume":"118","author":"M Hakimi","year":"2011","unstructured":"Hakimi M, et al. Parkinson\u2019s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm. 2011;118(5):795\u2013808.","journal-title":"J Neural Transm"},{"issue":"5","key":"175_CR30","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1523\/JNEUROSCI.5601-11.2012","volume":"32","author":"MS Moehle","year":"2012","unstructured":"Moehle MS, et al. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci. 2012;32(5):1602\u201311.","journal-title":"J Neurosci"},{"issue":"4","key":"175_CR31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1017\/S0317167100012099","volume":"38","author":"D Salat-Foix","year":"2011","unstructured":"Salat-Foix D, et al. Gastrointestinal symptoms in Parkinson disease: clinical aspects and management. Can J Neurol Sci. 2011;38(4):557\u201364.","journal-title":"Can J Neurol Sci"},{"issue":"10","key":"175_CR32","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.neurobiolaging.2009.10.016","volume":"32","author":"E Mutez","year":"2011","unstructured":"Mutez E, et al. Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol Aging. 2011;32(10):1839\u201348.","journal-title":"Neurobiol Aging"},{"issue":"9766","key":"175_CR33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(10)62345-8","volume":"377","author":"MA Nalls","year":"2011","unstructured":"Nalls MA, et al. Imputation of sequence variants for identification of genetic risks for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377(9766):641\u20139.","journal-title":"Lancet"},{"issue":"6676","key":"175_CR34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","volume":"392","author":"T Kitada","year":"1998","unstructured":"Kitada T, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605\u20138.","journal-title":"Nature"},{"issue":"3","key":"175_CR35","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/77060","volume":"25","author":"H Shimura","year":"2000","unstructured":"Shimura H, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25(3):302\u20135.","journal-title":"Nat Genet"},{"issue":"1","key":"175_CR36","doi-asserted-by":"crossref","first-page":"e1000298","DOI":"10.1371\/journal.pbio.1000298","volume":"8","author":"DP Narendra","year":"2010","unstructured":"Narendra DP, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010;8(1):e1000298.","journal-title":"PLoS Biol"},{"issue":"Pt 6","key":"175_CR37","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/brain\/awg142","volume":"126","author":"NL Khan","year":"2003","unstructured":"Khan NL, et al. Parkin disease: a phenotypic study of a large case series. Brain. 2003;126(Pt 6):1279\u201392.","journal-title":"Brain"},{"issue":"21","key":"175_CR38","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJM200005253422103","volume":"342","author":"CB Lucking","year":"2000","unstructured":"Lucking CB, et al. Association between early-onset Parkinson\u2019s disease and mutations in the parkin gene. N Engl J Med. 2000;342(21):1560\u20137.","journal-title":"N Engl J Med"},{"issue":"Pt 7","key":"175_CR39","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/brain\/awl114","volume":"129","author":"S Gandhi","year":"2006","unstructured":"Gandhi S, et al. PINK1 protein in normal human brain and Parkinson\u2019s disease. Brain. 2006;129(Pt 7):1720\u201331.","journal-title":"Brain"},{"issue":"1","key":"175_CR40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/1531-8249(200007)48:1<65::AID-ANA10>3.0.CO;2-L","volume":"48","author":"C Klein","year":"2000","unstructured":"Klein C, et al. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: Expanding the phenotype. Ann Neurol. 2000;48(1):65\u201371.","journal-title":"Ann Neurol"},{"issue":"5","key":"175_CR41","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ana.10524","volume":"53","author":"SA Oliveira","year":"2003","unstructured":"Oliveira SA, et al. Parkin mutations and susceptibility alleles in late-onset Parkinson\u2019s disease. Ann Neurol. 2003;53(5):624\u20139.","journal-title":"Ann Neurol"},{"issue":"Suppl 3","key":"175_CR42","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.23829","volume":"26","author":"SH Fox","year":"2011","unstructured":"Fox SH, et al. The movement disorder society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26 Suppl 3:S2\u201341.","journal-title":"Mov Disord"},{"issue":"Suppl 3","key":"175_CR43","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, et al. The movement disorder society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26 Suppl 3:S42\u201380.","journal-title":"Mov Disord"},{"key":"175_CR44","unstructured":"Grimes DA. Canadian guidelines on Parkinson\u2019s disease (on behalf of the Canadian Parkinson\u2019s Research Alliance). Can J Neurol Sci, 2012 (in press)."},{"issue":"5","key":"175_CR45","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/mds.21903","volume":"23","author":"E Lohmann","year":"2008","unstructured":"Lohmann E, et al. Are parkin patients particularly suited for deep-brain stimulation? Mov Disord. 2008;23(5):740\u20133.","journal-title":"Mov Disord"},{"issue":"14","key":"175_CR46","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.wnl.0000307748.11216.03","volume":"70","author":"E Moro","year":"2008","unstructured":"Moro E, et al. Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. Neurology. 2008;70(14):1186\u201391.","journal-title":"Neurology"},{"key":"175_CR47","first-page":"483530","volume":"2010","author":"N Bruin de","year":"2010","unstructured":"de Bruin N, et al. Walking with music is a safe and viable tool for gait training in Parkinson\u2019s disease: the effect of a 13-week feasibility study on single and dual task walking. Parkinsons Dis. 2010;2010:483530.","journal-title":"Parkinsons Dis"},{"issue":"11","key":"175_CR48","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1468-1331.2006.01547.x","volume":"13","author":"M Horstink","year":"2006","unstructured":"Horstink M, et al. Review of the therapeutic management of Parkinson\u2019s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section Part I: early (uncomplicated) Parkinson\u2019s disease. Eur J Neurol. 2006;13(11):1170\u201385.","journal-title":"Eur J Neurol"},{"issue":"2","key":"175_CR49","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.expneurol.2008.04.026","volume":"212","author":"A Ulusoy","year":"2008","unstructured":"Ulusoy A, Kirik D. Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson\u2019s disease? Exp Neurol. 2008;212(2):258\u201360.","journal-title":"Exp Neurol"},{"issue":"4","key":"175_CR50","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11910-011-0197-8","volume":"11","author":"J Witt","year":"2011","unstructured":"Witt J, Marks Jr WJ. An update on gene therapy in Parkinson\u2019s disease. Curr Neurol Neurosci Rep. 2011;11(4):362\u201370.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"11","key":"175_CR51","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1089\/hum.2007.082","volume":"18","author":"S Kato","year":"2007","unstructured":"Kato S, et al. Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type 1-based vector pseudotyped with rabies virus glycoprotein. Hum Gene Ther. 2007;18(11):1141\u201351.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"175_CR52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijpharm.2009.03.003","volume":"381","author":"O Preynat-Seauve","year":"2009","unstructured":"Preynat-Seauve O, et al. Pluripotent stem cells as new drugs? The example of Parkinson\u2019s disease. Int J Pharm. 2009;381(2):113\u201321.","journal-title":"Int J Pharm"},{"issue":"4","key":"175_CR53","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/WCO.0b013e32833b1f62","volume":"23","author":"LE Allan","year":"2010","unstructured":"Allan LE, Petit GH, Brundin P. Cell transplantation in Parkinson\u2019s disease: problems and perspectives. Curr Opin Neurol. 2010;23(4):426\u201332.","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"175_CR54","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cell.2011.06.019","volume":"146","author":"F Soldner","year":"2011","unstructured":"Soldner F, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011;146(2):318\u201331.","journal-title":"Cell"},{"issue":"1","key":"175_CR55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1474-4422(07)70327-7","volume":"7","author":"AH Schapira","year":"2008","unstructured":"Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson\u2019s disease. Lancet Neurol. 2008;7(1):97\u2013109.","journal-title":"Lancet Neurol"},{"issue":"7148","key":"175_CR56","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","volume":"447","author":"CS Chan","year":"2007","unstructured":"Chan CS, et al. \u2018Rejuvenation\u2019 protects neurons in mouse models of Parkinson\u2019s disease. Nature. 2007;447(7148):1081\u20136.","journal-title":"Nature"},{"issue":"11","key":"175_CR57","doi-asserted-by":"crossref","first-page":"780","DOI":"10.5692\/clinicalneurol.50.780","volume":"50","author":"M Murata","year":"2010","unstructured":"Murata M. The discovery of an antiparkinsonian drug, zonisamide. Rinsho Shinkeigaku. 2010;50(11):780\u20132.","journal-title":"Rinsho Shinkeigaku"},{"issue":"4","key":"175_CR58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1358\/dot.2010.46.4.1490077","volume":"46","author":"M Murata","year":"2010","unstructured":"Murata M. Zonisamide: a new drug for Parkinson\u2019s disease. Drugs Today (Barc). 2010;46(4):251\u20138.","journal-title":"Drugs Today (Barc)"},{"issue":"7","key":"175_CR59","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneur.64.7.nct60005","volume":"64","author":"A Storch","year":"2007","unstructured":"Storch A, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007;64(7):938\u201344.","journal-title":"Arch Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0175-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-012-0175-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0175-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T12:36:38Z","timestamp":1642163798000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-012-0175-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1007\/s11940-012-0175-8","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,1]]}}}